Related Experiment Video
Updated: Jan 5, 2026
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
1Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany. jongwhi.park@med.uni-heidelberg.de.
Abstract:
Targeting the epigenome has been considered a compelling treatment modality for several cancers, including gliomas. Nearly 80% of the lower-grade gliomas and secondary glioblastomas harbor recurrent mutations in isocitrate dehydrogenase (IDH). Mutant IDH generates high levels of 2-hydroxyglutarate (2-HG) that inhibit various components of the epigenetic machinery, including histone and DNA demethylases. The encouraging results from current epigenetic therapies in hematological malignancies have reinvigorated the interest in solid tumors and gliomas, both preclinically and clinically. Here, we summarize the recent advancements in epigenetic therapy for lower-grade gliomas and discuss the challenges associated with current treatment options. A particular focus is placed on therapeutic mechanisms underlying favorable outcome with epigenetic-based drugs in basic and translational research of gliomas. This review also highlights emerging bridges to combination treatment with respect to epigenetic drugs. Given that epigenetic therapies, particularly DNA methylation inhibitors, increase tumor immunogenicity and antitumor immune responses, appropriate drug combinations with immune checkpoint inhibitors may lead to improvement of treatment effectiveness of immunotherapy, ultimately leading to tumor cell eradication.
Insights
Epigenetic therapies targeting isocitrate dehydrogenase (IDH) mutations show promise for lower-grade gliomas. Combining epigenetic drugs with immunotherapy may enhance treatment effectiveness and eradicate tumors.
Area of Science:
- Oncology
- Epigenetics
- Cancer Therapeutics
Background:
- Lower-grade gliomas and secondary glioblastomas often have isocitrate dehydrogenase (IDH) mutations.
- Mutant IDH produces 2-hydroxyglutarate (2-HG), which disrupts epigenetic regulation by inhibiting demethylases.
- Epigenetic therapies have shown success in hematological cancers, prompting renewed interest in solid tumors like gliomas.
Purpose of the Study:
- To review recent advancements in epigenetic therapy for lower-grade gliomas.
- To discuss challenges and therapeutic mechanisms of epigenetic drugs in glioma research.
- To explore potential combination treatments involving epigenetic therapies.
Main Methods:
- Literature review of preclinical and clinical studies on epigenetic therapy in gliomas.
- Analysis of therapeutic mechanisms of epigenetic drugs, focusing on IDH-mutated gliomas.
- Exploration of combination strategies, particularly with immunotherapy.
Main Results:
- Epigenetic therapies, including DNA methylation inhibitors, are emerging as a viable treatment for gliomas.
- These therapies can enhance tumor immunogenicity and immune responses.
- Combination strategies, especially with immune checkpoint inhibitors, hold potential for improved outcomes.
Conclusions:
- Epigenetic targeting is a promising strategy for IDH-mutated gliomas.
- Further research into combination therapies, particularly with immunotherapy, is warranted.
- Optimizing epigenetic drug combinations could lead to more effective glioma treatment and tumor eradication.
Related Concept Videos
01:29Somatic to iPS Cell Reprogramming
01:32Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...